<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866461</url>
  </required_header>
  <id_info>
    <org_study_id>R01 3589819</org_study_id>
    <nct_id>NCT02866461</nct_id>
  </id_info>
  <brief_title>Endogenous Opioid Systems and Symptom Change in Fibromyalgia</brief_title>
  <official_title>Endogenous Opioid Systems and Symptom Change in Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to study brain mechanisms associated with symptoms and severity of&#xD;
      Fibromyalgia. This will be accomplished by relating results from PET scans to self-reported&#xD;
      and objective measures of disease severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine µ-opioid receptor (µOR)-mediated neurotransmission in&#xD;
      patients diagnosed with persistent pain, fibromyalgia (FM), and its relationship with pain&#xD;
      and affect measures. µOR activation is expected to take place in the following brain regions:&#xD;
      rostral and dorsal anterior cingulate (rACC, dACC), orbitofrontal cortex (OFC), thalamus&#xD;
      (THA), nucleus accumbens (NAC), amygdala (AMY), periaqueductal gray (PAG). Greater regional&#xD;
      activation is expected to be associated with improvements in clinical pain ratings and&#xD;
      affective state.&#xD;
&#xD;
      The endogenous opioid system and µ-opioid receptors (µORs) play a central role in the&#xD;
      regulation of pain, the pathophysiology of chronic pain syndromes, mood and emotion; this&#xD;
      system is dysregulated in persistent pain syndromes. A substantial body of literature&#xD;
      addressing these mechanisms has been developed in our laboratory, including recent data on&#xD;
      the cognitive and molecular mechanisms associated with reductions in pain, as well as trait&#xD;
      personality and genetic predictors of emotional effects in the context of pain.&#xD;
&#xD;
      Eighty individuals who have been diagnosed with FM and who fit the inclusion and exclusion&#xD;
      criteria will be enrolled in this 14-week protocol. An initial visit for informed consent&#xD;
      procedures and baseline characterization will then be scheduled, as well as the visits for&#xD;
      positron emission tomography (PET) and magnetic resonance imaging (MRI) procedures. Subjects&#xD;
      will return for testing after 6 and 14 weeks.&#xD;
&#xD;
      Volunteers will undergo imaging with structural and functional MRI and PET with&#xD;
      [11C]carfentanil to determine baseline µOR non-displaceable binding potential (BPND) and&#xD;
      changes in those BPND measures coinciding with symptom severity at the time of scanning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in mu opioid-mediated neurotransmission</measure>
    <time_frame>Change from baseline at 6 weeks</time_frame>
    <description>assessed via PET scanning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in Biomarkers of pain response</measure>
    <time_frame>Change from baseline at 6 weeks</time_frame>
    <description>serum cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Biomarkers of pain response</measure>
    <time_frame>Change from 8 weeks at 14 weeks</time_frame>
    <description>serum cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Pain</measure>
    <time_frame>Change from baseline at 6 weeks</time_frame>
    <description>assessed via questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Pain</measure>
    <time_frame>Change from 8 weeks at 14 weeks</time_frame>
    <description>assessed via questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in mu opioid-mediated neurotransmission</measure>
    <time_frame>Change from 8 weeks at 14 weeks</time_frame>
    <description>assessed via PET scanning</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <description>Observation</description>
    <arm_group_label>Fibromyalgia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be sampled at baseline to test for genes that may be associated with the function&#xD;
      of the chemical signals between nerve cells, function of hormones, and symptoms. The genetic&#xD;
      portion of the study is optional.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals diagnosed with Fibromyalgia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have met American College of Rheumatology (ACR) criteria for fibromyalgia for at least&#xD;
             1 year;&#xD;
&#xD;
          -  Willing to limit introduction of new treatments during the study;&#xD;
&#xD;
          -  Use of sleep aids no more than twice per week&#xD;
&#xD;
          -  18-55 years of age&#xD;
&#xD;
          -  right handed&#xD;
&#xD;
          -  capable of providing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concurrent untreated medical illnesses, autoimmune, or inflammatory disease;&#xD;
&#xD;
          -  Routine daily use of narcotic analgesics or history of substance abuse;&#xD;
&#xD;
          -  Concurrent participation in other therapeutic trials;&#xD;
&#xD;
          -  Pregnancy/ nursing;&#xD;
&#xD;
          -  Ongoing psychiatric illness;&#xD;
&#xD;
          -  Contraindications to PET or MRI methods;&#xD;
&#xD;
          -  Impairments that would prevent completion of the study protocol;&#xD;
&#xD;
          -  Use of sleep aids at frequency of more that twice per week;&#xD;
&#xD;
          -  Allergy to fentanyl&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chandni Sheth, PhD</last_name>
    <phone>801-587-1622</phone>
    <email>chandni.sheth@utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jon-Kar Zubieta, MD, PhD</last_name>
    <phone>801-742-1517</phone>
    <email>utahneuroimagelab@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Scott DJ, Heitzeg MM, Koeppe RA, Stohler CS, Zubieta JK. Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity. J Neurosci. 2006 Oct 18;26(42):10789-95.</citation>
    <PMID>17050717</PMID>
  </reference>
  <reference>
    <citation>Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007 Sep 12;27(37):10000-6.</citation>
    <PMID>17855614</PMID>
  </reference>
  <reference>
    <citation>Harris RE, Zubieta JK, Scott DJ, Napadow V, Gracely RH, Clauw DJ. Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on mu-opioid receptors (MORs). Neuroimage. 2009 Sep;47(3):1077-85. doi: 10.1016/j.neuroimage.2009.05.083. Epub 2009 Jun 6.</citation>
    <PMID>19501658</PMID>
  </reference>
  <reference>
    <citation>Martikainen IK, Peciña M, Love TM, Nuechterlein EB, Cummiford CM, Green CR, Harris RE, Stohler CS, Zubieta JK. Alterations in endogenous opioid functional measures in chronic back pain. J Neurosci. 2013 Sep 11;33(37):14729-37. doi: 10.1523/JNEUROSCI.1400-13.2013.</citation>
    <PMID>24027273</PMID>
  </reference>
  <reference>
    <citation>Peciña M, Martínez-Jauand M, Love T, Heffernan J, Montoya P, Hodgkinson C, Stohler CS, Goldman D, Zubieta JK. Valence-specific effects of BDNF Val66Met polymorphism on dopaminergic stress and reward processing in humans. J Neurosci. 2014 Apr 23;34(17):5874-81. doi: 10.1523/JNEUROSCI.2152-13.2014.</citation>
    <PMID>24760847</PMID>
  </reference>
  <reference>
    <citation>Martikainen IK, Nuechterlein EB, Peciña M, Love TM, Cummiford CM, Green CR, Stohler CS, Zubieta JK. Chronic Back Pain Is Associated with Alterations in Dopamine Neurotransmission in the Ventral Striatum. J Neurosci. 2015 Jul 8;35(27):9957-65. doi: 10.1523/JNEUROSCI.4605-14.2015.</citation>
    <PMID>26156996</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

